News

The program also includes FPA008 which is in its initial development stage for immunology as well as oncology indications. Under the terms of the agreement, Five Prime will

Resunab is a novel oral drug designed to target the resolution of chronic inflammation and debilitating fibrosis associated with disease progression in CF across all cystic fibrosis transmembrane

The Novartis portfolio is being offered to the Kenyan government, non-governmental organizations and other public-sector healthcare providers for USD 1 per treatment, per month. "Novartis and Kenya have

As part of the deal, Johnson & Johnson Innovation – JJDC will provide upfront payment and equity investment for engine, in addition to R&D funding. The deal will

The Phase 3 study, which is expected to begin in the first half of 2016, will be co-funded by Incyte and Merck. "We are very pleased to expand

FDA has provided recommendations specific to the moderate to severe chronic plaque psoriasis sNDA. Pfizer said that it will work with FDA to determine an appropriate path forward

"Our translational models give sponsors a high level of confidence when deciding to move a drug candidate into clinical development by providing insights into the pharmacological mechanisms of

By collaborating with University Health Network, the biotechnology company Novera will discover and develop novel therapeutic compounds identified through OICR’s drug discovery program. The company will coordinate the

Under the deal, ImaginAb will be responsible for conducting preclinical research using its immune imaging agent, IAB22M2C (a clinical anti-human CD8 probe), to detect T-cell trafficking, redirection and